L-β-galactoglucan ii and use thereof

Abstract

The present invention provides L-β-galactoglucan II. The present invention further provides a method for preparing L-β-galactoglucan II and a related extract. The L-β-galactoglucan II has good biological activity and can be used for improving the state of humans and animals.

Description

An L-β-galactoglucan II and its applications

[0001] Cross-reference is made to Chinese Patent Application No. 2024119073703, filed December 23, 2024, and Chinese Patent Application No. 2025105042935, filed April 22, 2025. The full text of the aforementioned Chinese patent applications is incorporated herein by reference.

[0002] Technical Field

[0003] This invention relates to the field of polysaccharide technology in microbiology, and more particularly to L-β-galactoglucan II produced by Agrobacterium FN01, its preparation method and application.

Claims

1. An L-beta-galactosan II having a repeating structural unit in the backbone as shown below 2. The L-beta-galactosan II according to claim 1, characterized in that, The average molecular weight is not less than 100,000 Da.

3. The L-beta-galactosan II according to claim 1, characterized in that, weight average molecular weight of about (6.5 ± 0.1) x 10 5 Da, 4 x 10 5 Da to 4.5 x 10 5 Da, or (1 ± 0.1) x 10 5 Da.

4. The L-β-galactoglucan II according to claim 1, characterized in that, Infrared spectrum has characteristic peaks at at least 3324 cm -1 , 2890 cm -1 , 1630 cm -1 , 1370 cm -1 , 1020 cm -1 , 893 cm -1 .

5. A fermentation broth containing L-β-galactoglucan II as described in claim 1, characterized in that, Its preparation method includes the following: Agrobacterium FN01 was inoculated into a fermentation broth and fermented to obtain a fermentation broth containing L-β-galactoglucan II. The fermentation broth included: a carbon source selected from one or more combinations of sorbitol, mannitol, and glycerol; a nitrogen source selected from one or more combinations of ammonia, yeast powder, and nitrate; inorganic salts; an antifoaming agent; and water; with a pH of 6.6–7.

2.

6. The fermentation broth of claim 5, wherein, The inorganic salt is selected from phosphates, dihydrogen phosphates, dihydrogen phosphates, and sulfates.

7. A polysaccharide crude containing L-beta-galactosan II according to claim 1, characterized in that, Its preparation method includes the following: (1) Take the fermentation broth as described in claim 5; (2) The fermentation broth was spray-dried to obtain crude polysaccharide containing L-β-galactoglucan II.

8. The method of claim 1 for the preparation of L-β-galactosan II, characterized in that, Includes the following: (1) Take the fermentation broth as described in claim 4; (2) Add hydrochloric acid or sodium hydroxide to the fermentation broth, heat, filter, and spray dry to obtain L-β-galactoglucan II; or, treat the fermentation broth with the sevage method, take the aqueous phase and spray dry to obtain L-β-galactoglucan II.

9. The use of L-β-galactoglucan II as described in claim 1, fermentation broth containing L-β-galactoglucan II, or crude polysaccharide containing L-β-galactoglucan II in the preparation of products that repair the intestinal barrier and / or regulate intestinal water and salt balance and / or regulate intestinal flora.

10. Use according to claim 9, characterized in that, The product is for the treatment and / or prevention of constipation.

11. The use of the L-β-galactoglucan II of claim 1, fermentation broth containing L-β-galactoglucan II, or crude polysaccharide containing L-β-galactoglucan II in the preparation of one of the following products: (1) Treatment and / or prevention of rhinitis; (2) Treatment and / or prevention of ulcers; (3) Relieves mucosal damage and / or repairs damaged mucosa; (4) Promotes the growth of livestock; (5) Improves the composition of breast milk in livestock; (6) Improves the balance of intestinal microbiota in animals and promotes digestive function in animals; (7) Enhance non-specific immune function; (8) Anti-aging; (9) Anti-inflammatory.

12. Use according to claim 11, characterized in that, The product for treating and / or preventing rhinitis is a product that has the effects of improving nasal inflammation, and / or reducing inflammatory cell infiltration, and / or repairing damaged nasal mucosa.

13. Use according to claim 11, characterized in that, The products mentioned for treating and / or preventing ulcers refer to products that include treatment and / or prevention of oral ulcers.

14. Use according to claim 11, characterized in that, The product for treating and / or preventing oral ulcers is one that includes relieving oral mucosal damage, and / or repairing damaged oral mucosa, and / or improving oral inflammation.

15. Use according to claim 11, characterized in that, In products that alleviate mucosal damage or / and repair damaged mucosa, the mucosa includes oral mucosa, nasal mucosa, gastric mucosa, and intestinal mucosa.

16. Use according to claim 11, characterized in that, Promoting the growth of domesticated animals refers to promoting the growth of domesticated animals of different ages.

17. The use according to claim 11, characterized in that, The term "raised animals" refers to raising young animals.

18. The use according to claim 11, characterized in that, The animals being raised are selected from livestock and pets; the livestock include pigs, cattle, and sheep; the pets include dogs and cats.

19. The use according to claim 11, characterized in that, Improving the composition of breast milk in livestock refers to increasing the fat content in sow's milk and / or reducing urea nitrogen in breast milk.

20. The use according to claim 11, characterized in that, Products that improve the balance of gut microbiota in animals and promote their digestive function, wherein the animal refers to a human or a domesticated animal.

21. The use according to claim 11, characterized in that, The enhancement of non-specific immune function refers to increasing the number of immune cells and / or regulating the function of immune cells.

22. The use according to claim 11, characterized in that, The enhancement of non-specific immune function refers to increasing the number of macrophages.

23. The use according to claim 11, characterized in that, The anti-aging effect refers to inhibiting β-galactosidase activity, increasing SOD activity, and / or increasing telomerase activity.

24. The use according to claim 11, characterized in that, The anti-inflammatory effect refers to the treatment and / or prevention of inflammation caused by lipopolysaccharide.

25. The use according to claim 11, characterized in that, The term "anti-inflammatory" refers to reducing the abnormal expression of inflammatory factors.

26. The use according to claim 26, characterized in that, The inflammatory factors were selected from pro-inflammatory interleukins.

Images